The need for improved risk stratification in chronic critical limb ischemia  by Chung, Jayer et al.
From
Su
Auth
Rep
Su
M
(e
The
to
m
0741
Cop
httpThe need for improved risk stratiﬁcation in chronic
critical limb ischemia
Jayer Chung, MD, J. Gregory Modrall, MD, and R. James Valentine, MD, Dallas, Tex
Vascular surgeons are well acquainted with chronic critical limb ischemia (CLI), the most severe manifestation of
peripheral arterial disease, with patients presenting with ischemic rest pain or ulcerations, or both. Epidemiologic data
predict a burgeoning epidemic of CLI within the United States, commensurate with the increasing incidence and prev-
alence of atherosclerotic risk factors, especially age and diabetes. Untreated, the risk of major amputation (above the
ankle) or death, or both, ranges between 20% and 40% at 1 year. Current open and endovascular therapies have imperfect
results, diverse treatment options, and recommendations that are often conﬂicting and confuse physicians, industry, and
patients alike. The best treatment options are ideally evaluated by prospective, randomized controlled trials. However,
these have proven impractical in CLI because the rapid evolution of devices and techniques has outstripped the ability to
measure outcomes and compare treatment options. Alternatively, risk-stratifying models have been proposed to allow
physicians, patients, and industry to objectively evaluate new therapeutics and devices as they evolve. These models are
developed from prospective cohorts to identify and quantify variables that can subsequently predict outcome in individual
patients. The risk stratiﬁcation models can also compare CLI outcomes between physicians and institutions, supporting
quality assessments, and compensation decisions within Accountable Care Organizations under the Affordable Health
Care Act (ACA). Widespread adoption of risk-stratiﬁcation schemes has yet to occur, despite the critical need for such a
tool in CLI, because present models lack optimal predictive ability and generalizability. The passage of the ACA ampliﬁes
the importance of developing an improved risk-stratiﬁcation tool to ensure equitable quality assessments and compen-
sation. This review presents current risk-stratiﬁcation models for CLI with a summary of the respective strengths and
limitations of each. Future research is needed to simplify and improve the accuracy and generalizability of risk stratiﬁ-
cation in CLI. (J Vasc Surg 2014;60:1677-85.)Chronic critical limb ischemia (CLI) is the most severe
manifestation of peripheral arterial disease (PAD) and
encompasses all patients with symptoms of chronic rest
pain, ulcerations/gangrene, or both, with concomitant
objective evidence of arterial insufﬁciency. This includes
all patients at Fontaine stages III and IV and Rutherford
classes 4 to 6.1-3 The term CLI was initially coined in the
early 1980s and was initially intended to describe patients
with arterial insufﬁciency, rest pain, or gangrene in the
absence of diabetes.4
Untreated, CLI portends a grim prognosis, with up to
40% of patients requiring a major amputation (either an
above-the-knee or below-the-knee amputation) #1 year
of diagnosis.5 At 5 years, patients with symptomatic
PAD have a 20% to 30% risk of myocardial infarction,
stroke, or death,1 with CLI patients at the higher end
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between 10% and 40%.1
Epidemiologic data predict a burgeoning epidemic of
CLI within the United States (U.S.) Current estimates of
the incidence and prevalence of CLI vary, with the most
consistent approximations of the incidence ranging
between 500 and 1000 new cases/year/million in an
American or Western European population.1 This likely
underestimates the true incidence and prevalence of disease
in the U.S. due to the frequent underdiagnosis of PAD.6
Moreover, the population is growing, with an
increasing proportion of the population aged >65 years.
By 2030, an estimated 20% of the population will be
aged >65 years, which is double the current proportion
of people aged >65 years.7 Combined with the increasing
incidence and prevalence of atherosclerotic risk factors,
especially diabetes and obesity,8 the current and projected
incidence and prevalence of CLI is likely signiﬁcantly
higher than published estimates.PERSISTENT SUBOPTIMAL OUTCOMES IN CLI
Outcomes of interventions for CLI, unfortunately,
remain imperfect, magnifying the signiﬁcance of the loom-
ing epidemic of CLI. Summarized results of prospective
randomized data of open surgical bypass for CLI show
that w25% of patients fail to survive with an intact limb
at 1 year from the infrainguinal revascularization attempt
(Table I).2,9-12 Less than 15% of patients ultimately achieve
the ideal surgical result of an uncomplicated bypass,1677
Table I. Summarized results of open infrainguinal bypass (IAB) for chronic critical limb ischemia (CLI)a
First author Journal Year Design No. Main ﬁndings
Adam11 Lancet 2005 PRCT comparing IAB vs angioplasty in CLI at
5.5 years
452 12-month AFS: 68% in each arm
Conte9 J Vasc Surg 2006 PRCT comparing IAB performed with ex vivo
vein graft treatment vs placebo in CLI
1404 12-month AFS or intervention-free
survival: 50.1% vs 48.6%
Nehler10 J Vasc Surg 2007 PRCT comparing IAB performed with adjunctive
lipoecraprost vs placebo in CLI
284 6-month AFS: 80% vs 74%
Bradbury12 J Vasc Surg 2010 PRCT comparing IAB vs angioplasty in CLI at
8 years
452 Survivorship improved for IAB arm at
>2 years: HR, 0.61 (95% CI, 0.5-0.75)
Conte2 J Vasc Surg 2009 Pooled data set of above trials of open autologous
vein infrainguinal bypass in CLI
838b Pooled AFS at 1-year: 76.5%
AFS, Amputation-free survival; CI, conﬁdence interval; HR, hazard ratio; PRCT, prospective, randomized controlled trial.
aNo trial showed a statistically signiﬁcant difference between placebo and treatment arms.
bUsed only patients in the open surgery control groups, resulting in the cohort of 838.
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tom relief, and freedom from reinterventions.13
Because of modest outcomes and signiﬁcant morbidity
after infrainguinal bypass for CLI, many practitioners favor
endovascular interventions. Recent population-based
studies show that endovascular interventions are more
commonly performed for CLI compared with open proce-
dures.14 Results for endovascular interventions vary widely,
with a broad range of primary and secondary end points
evaluated; however, overall clinical success after endovascu-
lar interventions is modest as well, ranging between 31%
and 74%.15 This deﬁcit persists despite the rapid increase
in new techniques and devices to revascularize patients’
limbs for CLI. The lack of clear superiority of any modality,
coupled with persistent compromised outcomes and a
myriad of therapeutic options, has obscured the interpreta-
tion of trials regarding the outcomes in CLI.
Patient-centric functional outcomes, such as mainte-
nance of ambulation, wound-healing, and domiciliary
status, remain incompletely evaluated end points in the
CLI population, with only retrospective analyses providing
insight into these end points. Considering the modest re-
sults after revascularization, limited life expectancy, and
morbidity associated with revascularization attempts, these
end points may ultimately bemore germane when designing
future comparative effectiveness trials between endovascular
and open surgical reconstructions inCLI.16-19 Available data
suggest equally poor outcomes using these end points.
Taylor et al16 showed that at 5 years after revascularization,
maintenance of ambulationwas 70.6% and thatmaintenance
of independent domiciliary status was 81.3%. Complete
wound healing, deﬁned as the healing of all ischemic and
surgical wounds, was <50% at 6 months.17
Revascularization is a mainstay of therapy because
nonoperative interventions for CLI are limited to investiga-
tional use only. Development of nonoperative options for
CLI is signiﬁcant: Up to 50% of patients are not candidates
for revascularization due to medical comorbidities, lack of
conduit, extensive gangrene, or vascular anatomy that
cannot be reconstructed.10 The recently completed Use
of Tissue Repair Cells in Patients with Peripheral Arterial
Disease to Treat Critical Limb Ischemia (RESTORE-CLI)trial19 shows promise with Ixmyelocel-T (Aastrom Biosci-
ences, Inc, Ann Arbor,Mich), which is used to expand the pa-
tient’s own bone marrow-derived mononuclear cells, which
stimulates angiogenesis and encourages the development of
arterial collaterals. Powell et al19were able to show an increase
in amputation-free survival (AFS) by 32% in the treatment
arm, although this was not statistically signiﬁcant. These
patients represent an important comparison group when
outcomes in CLI are evaluated.
Primary major amputations remain an important treat-
ment modality in patients with CLI, although rates appear
to be decreasing.14 Although frequently considered a treat-
ment failure, timely above-the-knee or below-the-knee am-
putations may be preferable in some patients. In fact, there
is a segment of the CLI population whose ambulatory out-
comes after major amputation appear to rival outcomes of
CLI patients who undergo revascularization.18 Patients
undergoing major amputation also represent an important
comparison group when outcomes in CLI are evaluated.
THE COST OF CLI
Cost analyses are increasingly salient in the U.S. as
health care costs continue to spiral, currently amounting
tow18% of the U.S. gross domestic product20; moreover,
the rate of growth is becoming unsustainable. In an attempt
to curb health care expenditures, the U.S. Congress passed
the Affordable Health Care Act (ACA) in 2010.21
For all of the aforementioned reasons, comparative
effectiveness research (CER) has become particularly
germane to the vascular surgery population, for whom
care is often laborious, expensive, and complex due to
the patients’ multiple comorbidities.13 Cost-effectiveness
comparisons have been sparse in the literature, with very
few having been performed in the past 20 years. Many of
these studies failed to evaluate patientcentric outcomes,
such ambulation and wound healing, and also failed to
use more sophisticated measurement techniques, such as
microcosting, activity-based accounting, or transition
cost-accounting. Rather, they simply used claims data,
modeling, or other proxies for estimating the costs22;
hence, accurate comparisons between different strategies
are glaringly absent in the CLI literature.
Fig. Simpliﬁed schematic representation shows the derivation and
validation of a prototypical risk-prediction model.
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ing that infrainguinal bypasses or other traditional revascu-
larization techniques are more cost-effective than primary
amputation.23 Infrainguinal bypass may be less cost-
effective compared with endovascular therapies.24 Other
more recent modelling data suggest that open revasculariza-
tion is the most cost-effective treatment strategy, with the
caveat that if wound healing rates were >37%, or if proce-
dural costs were decreased by 42%, then endovascular-ﬁrst
revascularization strategies were the most cost-effective.25
IMPORTANCE OF RISK STRATIFICATION
IN CLI
Better risk prediction is instrumental to (1) comple-
ment patient and physician decision-making about which
patients will beneﬁt from speciﬁc vascular interventions
and (2) evaluate and improve risk-adjusted outcomes and
use of resources. The absence of a mechanism to accurately
risk-stratify CLI patients partly explains the relative dearth
of quality CER in CLI. This is especially important in light
of the passage of the Affordable Health Care Act in 2010,
which has led to the creation of Accountable Care Organi-
zations (ACOs), which are designed to align physician
compensation by Medicare with the quality of the out-
comes of their procedures. Appropriate risk stratiﬁcation
is essential to ensure appropriate comparisons among inter-
ventions, practitioners, and institutions and permit equitable
compensation in ACOs.21 An example of this need is evident
in articles regarding the role of specialty training and out-
comes in lower extremity interventions. Although some au-
thors argue that specialty training predicts outcomes,26
others argue that the indication for the intervention or
severity of ischemia more strongly predicts outcome.27
Improved risk stratiﬁcation could clarify these differences,
thereby permitting equitable comparisons across practi-
tioners.Moreover, the improved ability to compare different
outcomes would simplify the patient consent process, which
could perhaps mitigate the detrimental effects of medico-
legal activity. The prototypical development of a risk predic-
tion model is outlined in the Fig.28-33
CER in CLI has been hampered by two main factors.
The ﬁrst is study heterogeneity regarding the deﬁnition
of CLI and the end points. Inclusion and exclusion criteria
among CLI studies differ signiﬁcantly, resulting in consid-
erable variability in the results and hampering the interpret-
ability and generalizability of the outcomes. This reﬂects
the heterogeneity of conditions that present with a combi-
nation of lower limb infection, ischemia, and ulceration
that ultimately result in limb loss. Moreover, multiple
end points exist for study, without a deﬁnite consensus as
to which are the best for study.2
The second factor is failure to capture differences in
comorbidities and extent of disease. The initial deﬁnition
of CLI failed to include diabetic patients, who currently
comprise a signiﬁcant proportion of patients presenting
with limb-threatening ischemia.4 Recent models fail to
consistently stratify by whether the patient underwent
endovascular therapies, the vascular anatomy,32 woundseverity,34 and pre-existing medical adherence to athero-
sclerotic risk factor managment.35 These unmeasured dif-
ferences can result in treatment and control groups that
are not comparable, even within prospective, randomized
controlled trials (PRCTs). Although PRCTs theoretically
control for unmeasured confounders, when the PRCTs
show a lack of a treatment effect, determining whether
the lack of an effect is due to a true lack of effect or from
an unmeasured bias is difﬁcult.36
Further, PRCTs provide the best evidence but pose
several difﬁculties when studying CLI. First, PRCTs
Table II. Summary of risk-prediction models in critical limb ischemia (CLI)
First author Journal Year Study base No. Designed end point(s) AUC C statistic
Externally validated
Biancari28 World J Surg 2007 FINNVASC registry of
open revascularizations
3925 30-day AFS 0.506 0.630
Schanzer29 J Vasc Surg 2008 Nested cohort of PIII data 1404 1-year AFS 0.582 0.634
Bradbury32 J Vasc Surg 2010 Nested cohort of BASIL
data
452 2-year mortality 0.651
No external validation
Taylor37 Ann Surg 2003 Single-center prospective
cohort
137 6-month mortality,
patency, limb
salvage, functional
outcomes
Not performed
Gupta39 J Vasc Surg 2012 NSQIP data 2007-2009 9556 30-day mortality 0.81
Meltzer40 J Vasc Surg 2013 NSQIP data 2007-2009 3275 30-day M&M 0.61 0.77
Mills34 J Vasc Surg 2013 Not applicable Not applicable Not deﬁned Not applicable
AFS, Amputation-free survival; AUC, area under the curve; BASIL, Bypass vs Angioplasty in Severe Ischaemia of the Leg; FINNVASC, National vascular
registry in Finland; M&M, morbidity and mortality; NSQIP, National Surgical Quality Improvement Program; PIII, PREVENT III (Edifoligide for the
Prevention of Infrainguinal Vein Graft Failure).
JOURNAL OF VASCULAR SURGERY
1680 Chung et al December 2014generally take a considerable length of time to complete.
Owing to the rapid evolution of new devices, therapeutics,
and techniques, the signiﬁcance of results at the completion
of the trial are often reduced because they may compare
outdated therapies. This issue was evident in the Bypass vs
Angioplasty in Severe Ischaemia of the Leg (BASIL) trial,
which is the only published trial to compare endovascular
and open revascularization for chronic CLI.11,12 The BASIL
study, however, deﬁned endovascular therapies as percuta-
neous balloon angioplasties only. By the time the study
had been complete, multiple other registries had shown
the lack of efﬁcacy of balloon angioplasty alone compared
with adjunctive stenting, in several of the arterial beds,
such that adjunctive stenting was commonly performed in
modern practices.14 This grossly limited the generalizability
of the results of the BASIL trial to modern practice.
Furthermore, enrolling patients into a placebo arm for
CLI is difﬁcult ethically and pragmatically because the out-
comes of untreated CLI are already known to be markedly
inferior to revascularization. Finally, PRCTs are signiﬁ-
cantly more expensive to perform than single-armed pro-
spective evaluations of individual interventions. When
considering the aforementioned difﬁculties, PRCTs are
becoming increasingly impractical in the study of CLI
and may slow the pace of innovation and eventual evolu-
tion of therapies for CLI. Therefore, many experts in the
ﬁeld are advocating for a common trial design that will
allow physicians and industry to objectively evaluate new
therapeutics and devices as they evolve.2,36
CURRENT EXTERNALLY VALIDATED
MODELS TO RISK-STRATIFY PATIENTS
AND OUTCOMES IN CLI
Biancari et al28 were the ﬁrst group to attempt to risk-
stratify patients with CLI, with the development of the
National vascular registry in Finland (FINNVASC) score
(Table II). This score determined the risk of a patient under-
going amajor amputation or dying#30 days of an open sur-
gical revascularization. The authors used the FINNVASCRegistry, which included details on 5709 CLI procedures
between 1991 and 1999 from ﬁve university hospitals, 16
central hospitals, and four district hospitals.28 The FINN-
VASC Registry is the second largest of the data sets used to
develop a prediction model. They deﬁned CLI as the pres-
ence of Fontaine stages III and IV disease. They limited their
evaluation to 3925procedures performed as an open surgical
revascularization only. Approximately half of the patients
were used to create a model, and the remaining patients
were used to internally validate the model.
The authors identiﬁed four variables that were indepen-
dently predictive of 30-day AFS: a history of diabetes melli-
tus, coronary artery disease, gangrene at presentation, and
the need for an urgent operation. Each of these variables
was assigned1point todevelop the risk score.Patientshad sta-
tistically signiﬁcantly different 30-day AFS in each of the
scoring strata, 0-4. The area under the curve (AUC), which
is ameasure of the ability of themodel topredict the outcome,
was 0.611 (P < .0001), which means that the FINNVASC
score was able to predict 61.1% of the time whether patients
underwent a major amputation or died at 30 days.
The results were statistically signiﬁcant, but the model
had several weaknesses due to the deﬁciencies in the data
collection and unmeasured variables (Table III). The
model did not include several variables that have been
shown to be predictive of AFS in other studies, including
a history of tobacco abuse, hyperlipidemia, and baseline
ambulatory status. Also absent were data regarding the
severity of the wound(s) at presentation, atherosclerotic
risk factor management, and angiographic patterns of dis-
ease. Finally, the model limited their evaluation to open
infrainguinal revascularizations and evaluated outcomes at
30 days only. Hence, endovascular outcomes and end
points >1 month cannot be evaluated with this model.
Schanzer et al29 followed the FINNVASC group by
performing a nested-cohort study from the Edifoligide
for the Prevention of Infrainguinal Vein Graft Failure
(PREVENT III [PIII]) trial,9 which consisted of 1404
infrainguinal bypass patients from >80 Canadian and
Table III. Strengths and weaknesses of current risk-stratiﬁcation schema developed to compare outcomes in chronic
critical limb ischemia (CLI)
First author Journal Year
Predictive variables in the
model/score Strengths Weaknesses
Externally validated
Biancari28 World J Surg 2007 d DM d Large number of patients d 30-day outcomes only
d CAD d Multicenter registry of
university and community
hospitals
d Open revascularizations only
d Gangrene d Missing signiﬁcant variables
d Urgent operation d Finland only
Schanzer29 J Vasc Surg 2008 d Dialysis dependence d Nested, multicenter cohort of
prospective randomized data
d Highly selective group of
patients
d Tissue loss d Missing signiﬁcant variables
d Age $75 years
d Hct #30%
d CAD
Bradbury32 J Vasc Surg 2010 d Tibial angiogram scores d Nested, multicenter cohort of
prospective randomized data
d Highly selective group of
patients
d Severity of ischemia d Inclusion of angioplasty
subjects
d Missing signiﬁcant variables
d Presence of pedal necrosis d Evaluated survival at 2 years only
d BMI, age, serum Cr,
tobacco abuse
No external validation
Taylor37 Ann Surg 2003 d Arteriographic variables d Internally validated d Not limited to CLI only
d Ischemic severity
(claudication or CLI)
d No indication bias, with
inclusion of all PAD patients
d 6-month outcomes only
d Ambulatory status, age,
obesity, CAD
d Technical factors (lack of
conduit, redo surgery)
Gupta39 J Vasc Surg 2012 d Age d Best predictive ability d 30-day mortality only
d Chronic steroid use,
COPD, development of
SIRS, ESRD, rest pain
on presentation, and
dependent functional
status
d Derived from large data set d Not externally validated
d Only infrainguinal bypasses
d Mix of claudicant and CLI
patients
Meltzer40 J Vasc Surg 2013 d Age >75 years d Excellent predictive ability d 30-day mortality and
morbidity only
d Prior amputation or
revascularization, tissue
loss, hemodialysis, severe
cardiac disease, emergency
surgery
d Derived from large data set d Only infrainguinal bypasses
d Functional and total
dependence
Mills34 J Vasc Surg 2013 d Location, depth, and size
of the ulcer
d Inclusion of wound and
infectious parameters
d Complex, especially as it needs
to be combined with other risk
stratiﬁcation models
d Associated infection d No indication bias, with
inclusion of all wounds
d Not validated
d Severity of ischemia d No outcome speciﬁed
BMI, Body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; Cr, creatinine; DM, diabetes mellitus; ESRD, end-stage
renal disease; Hct, hematocrit; PAD, peripheral arterial disease; SIRS, systemic inﬂammatory response syndrome.
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953 of these patients, and the remaining 451 were used to
internally validate the model. Subsequently, a cohort of
716 infrainguinal bypass patients from two university hos-
pitals and one community hospital was used to externally
validate the model.The independent predictors of AFS were used to
derived weighted point scores for each variable, which
was used to generate a risk score for major amputation or
death for each patient at 1 year. Four independent predic-
tors of 1-year AFS were initially identiﬁed: dialysis depen-
dence, the presence of tissue loss, age >75 years, and a
JOURNAL OF VASCULAR SURGERY
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generate the PIII CLI risk score, ranging between 0 and
12. The PIII risk score was subsequently modiﬁed to
include anemia, deﬁned as a baseline hematocrit
of <30%, and found to consistently predict AFS in external
surgical outcomes data sets.30
However, the PIII risk score was also limited to infrain-
guinal bypass surgeries, which currently comprise the mi-
nority of the procedures performed for CLI in a modern
vascular surgery practice.14 Similar to the FINNVASC
score, the PIII score also failed to analyze several variables
that have been found to be predictive of AFS. The PIII
score and FINNVASC scores were subsequently compared
in an external data set of 1425 patients undergoing either
endovascular revascularizations, infrainguinal bypasses, or
both.31 This study revealed bothmodels were onlymodestly
predictive of 30-day and 1-year AFS, with an AUC for
1-year AFS of 0.634 for the PIII risk score and an AUC of
0.630 for the FINNVASC model (Tables II and III).
The sole PRCT studying the role of endovascular vs
open surgical revascularization in CLI was the BASIL trial
from the United Kingdom (Table II).11,12 This trial
compared the AFS of patients randomly allocated to
receive balloon angioplasty only or infrainguinal bypass
surgery ﬁrst, and recruited 452 patients from 27 hospitals.
The data from this trial were subsequently used to develop
a prediction model for 2-year survival only, given the pa-
tients’ baseline characteristics.32 The rationale for the
end point was drawn from the ﬁndings of the original BA-
SIL trial, which showed that the infrainguinal bypass arm
had a statistically signiﬁcant increase in AFS for patients
who survived >2 years. The authors used 75% of randomly
selected patients from the nested cohort and found that
the baseline variables predictive of death at 2 years were
the severity of ischemia (deﬁned by the number of
Doppler signals present at the ankle and the maximum
ankle pressure obtained), the severity of tibial and pedal
obstructions (deﬁned as the Bollinger angiogram scores),
presence of pedal necrosis, age, serum creatinine, and
smoking status. A history of myocardial infraction or
angina and a history of stroke or transient ischemic attack
were also included in the model because they were deﬁned
a priori as signiﬁcant determinants of survival.32 With these
variables, the authors found that the proportion of survi-
vors at 6 months, 1 year, and 2 years was 85%, 77%,
and 65%, respectively.32
The BASIL score was subsequently externally validated
and compared with the FINNVASC and modiﬁed PIII
scores in a retrospective cohort of 342 individuals undergo-
ing infrainguinal bypass or angioplasty, or both. With
respect to survival only at 12 months, the BASIL score
was best able to predict mortality, with an AUC of 0.651.
This compared with the FINNVASC and modiﬁed PIII
scores, which had AUCs of 0.506 and 0.582, respectively.33
The BASIL score was more comprehensive than the
prior scoring systems but also failed to include data on
the multitude of endovascular interventions currently per-
formed in vascular practices (Table III). It is unclearwhether the BASIL results remain valid in the current
era of vascular surgery in which angioplasty alone is rarely
performed. Moreover, the BASIL score, although having
data on a wider range of variables, still fails to include
data regarding the severity of pedal necrosis at presenta-
tion, the quality of medical risk factor management at pre-
sentation, and the quality of wound care. The BASIL score
is also more complex than the prior systems, limiting its
applicability to daily use. Finally, the outcomes were
limited to survival only, leaving practitioners to extrapolate
other outcomes, such as limb salvage, from other scoring
systems.
MODELS LACKING EXTERNAL VALIDATION
Mills et al34 has also proposed a new scoring scheme,
using the Delphi consensus process, that is designed to
risk-stratify patients presenting with ischemic ulceration
using the Wound, Ischemia, and Foot Infection (WIfI) sys-
tem. This is particularly important, because the incidence
and prevalence of diabetes is increasing, which may be
altering the morphology and distribution of vascular insuf-
ﬁciency in patients presenting with ischemic ulcerations.34
The WIfI system categorizes the variables of wound depth,
location, and sepsis in conjunction with the severity of pre-
senting ischemia, as deﬁned by the ankle-brachial index or
ankle pressures, toe pressures, or transcutaneous oxygen
measurements. This system recommends that patients
with diabetes be stratiﬁed by the presence or absence of
neuropathy as well as by the severity of the toe pressure
decrements. Wounds are recategorized also after control
of infection and debridement. The intent of the WIfI sys-
tem is that it is to be used in conjunction with a comorbid-
ity stratiﬁcation system and an anatomic score to aid in
clinical decision making and for clinical trials. The WIfI
system has yet to be validated against any data set, and
the added complexity may decrease its clinical utility
(Tables II and III).
The Lower Extremity Grading System (LEGS) is the
only directive stratiﬁcation tool developed to guide the
treatment of patients presenting with PAD, including those
with claudication (Table II).37 This was initially developed
as a clinical decision-making aid to determine whether the
patient should undergo traditional open vs endovascular
revascularization in CLI. The score included arteriographic
variables, ischemic severity (claudication or CLI), ambula-
tory status, age, obesity, coronary artery disease, and tech-
nical factors, such as lack of conduit, and redo surgery. The
score was prospectively validated within the authors’ insti-
tution, showing that use of the scoring system resulted in
acceptable 6-month mortality, limb salvage, and functional
outcomes in the scored patients that was superior to limb
salvage, patency, and ambulatory status outcomes achieved
without use of the LEGS scoring mechanism.38 The LEGS
score has not been externally validated, precluding its use as
a risk-stratiﬁcation tool for clinical trials and outcomes
assessments. Moreover, the inclusion of claudicant patients
makes comparisons with CLI-only populations problem-
atic. However, the LEGS scoring system does include all
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amputation, which more accurately represents the decisions
required of vascular specialists (Table III).
Two groups used the American College of Surgeons
National Surgical Quality Improvement Program data
from 2007 through 2009 to develop CLI risk-prediction
models. Gupta et al39 (Table II) developed a model to pre-
dict 30-day mortality, using outcomes data from 9556
patients undergoing an infrainguinal bypass. Independent
predictors of 30-day mortality included age, a history of
chronic steroid use, chronic obstructive pulmonary disease,
development of the systemic inﬂammatory response syn-
drome, dialysis dependence, rest pain on presentation,
and dependent functional status. The C statistic for this
model was 0.81, meaning that the model correctly identi-
ﬁed 81% of those who died after an infrainguinal bypass.
Oddly, the authors’ risk calculator found that tissue loss
at presentation did not independently predict death, as
was seen in the BASIL model,32 or in the subsequent
model studying CLI-only patients.
This model has not been externally validated and lacks
data regarding the severity of pedal necrosis, severity of
arterial disease burden, and quality of baseline medical
therapy. The model also included patients with claudica-
tion, clouding the ability to predict outcomes in CLI
patients. Moreover, the end point for that study was
limited to survival after infrainguinal bypass. However,
several novel predictors of 30-day mortality, such as
chronic obstructive pulmonary disease and postoperative
systemic inﬂammatory response syndrome, which warrant
further study (Table III).
The Comprehensive Risk Assessment for Bypass
(CRAB) also used the American College of Surgeons
National Surgical Quality Improvement Program data set
to develop a risk-prediction model for 30-day morbidity
and mortality (M&M) in CLI patients undergoing infrain-
guinal bypass (Table II).40 A total of 3275 patients were
used to derive a prediction model of the composite end
point of M&M, with 1620 patients in the internal valida-
tion set used to validate the model against M&M as well
as mortality and morbidity alone. This study has a smaller
study base that the Gupta et al39 study due to the inclusion
only of patients with International Classiﬁcation of
Diseases, Ninth Revision codes consistent with CLI.
Independent predictors of 30-day M&M included age
>75 years, prior amputation or revascularization, tissue
loss, hemodialysis, severe cardiac disease, emergency sur-
gery, partial functional dependence, and total functional
dependence. Integer scores were assigned to each of these
predictors based on the magnitude of the effect attributed
to each of these variables on multivariable analysis. The C
index of the model for M&M was 0.68 and was 0.61 for
morbidity alone and 0.77 for mortality alone. This model
has also not been externally validated and is limited only
to infrainguinal bypass patients and evaluation of 30-day
outcomes. However, this model has some of the best
discriminatory ability in the literature and also warrants
further evaluation (Table III).SUMMARY OF CRITICAL GAPS IN
KNOWLEDGE REGARDING RISK
STRATIFICATION IN CLI
Risk stratiﬁcation in CLI is in its infancy. The existing
risk models have demonstrated modest predictive abilities.
These risk-stratiﬁcation systems are heterogeneous in pre-
dictor variables and outcomes assessed. For instance, the
inclusion of endovascular therapies is not uniform nor is
the evaluation of the severity of pedal necrosis or the ade-
quacy medical risk-factor management and other known
risk factors of AFS. Moreover, all of the scoring systems
have difﬁculties with generalizability related to the patient
population that they were derived from or to the lack of
rigorous external validation from data sets outside of their
institutions. Confounding by indication41 is also a signiﬁ-
cant problem, because many of the derivation sets included
only infrainguinal bypasses or angioplasties, but not both.
This means that the estimates of predictor variables cannot
necessarily be extrapolated to an entire population of CLI
patients. Hence, only the LEGS34 and WIfI33 scoring sys-
tems are applicable to all patients who may present to a
vascular specialist. Finally, as investigators discover novel
baseline, intraoperative, and postoperative predictors of
outcomes in CLI, the scoring systems become increasingly
complex.
Future scoring systems may beneﬁt from the inclusion
of other variables that are variably present in prior studies
or absent altogether. This may help to improve the predic-
tion capabilities, as evidenced by Gupta et al,39 who
showed that use of previously unstudied baseline and post-
operative variables improved the predictive ability of his
model relative to prior models. Moreover, inclusion of pa-
tients from populations that most closely mimic that of the
CLI population that presents to a vascular specialist’s clinic
is critical to avoid confounding by indication41 and
improve the ability of the risk-scoring systems to predict
AFS. Decreasing heterogeneity in the predictive models
can be improved by consensus on the optimal end points
for study.2 Information technologies may assist in
decreasing the complexity entailed with the scoring sys-
tems, ultimately improving the ease of use and dissemina-
tion. Finally, future scoring mechanisms would beneﬁt
from improved external validation in large data sets that
are becoming increasingly available. Although no risk strat-
iﬁcation tool will perfectly forecast a patient’s outcome,
improved risk stratiﬁcation certainly has the potential to
greatly improve patient and physician decision making,
adjudication of quality assessments, and compensation in
ACOs.
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